ASCO to spotlight pancreatic cancer innovation beyond KRAS

While Revolution Medicines’ Phase III pancreatic cancer data are among the most anticipated clinical results at this year’s ASCO conference, the broader abstract set shows biopharmas widening the innovation playbook in a cancer type that has seen few therapeutic advances.

Pancreatic cancer appears set to be a major focus of the 2026 American Society of Clinical Oncology (ASCO) conference, with abstracts released Friday highlighting new data spanning KRAS pathway inhibitors, antibody-drug conjugates (ADCs), bispecific antibodies, novel targets and liquid biopsy-based diagnostics...